Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Has Consensus Price Target of $8.75

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $9.00.

Several equities analysts recently issued reports on PYXS shares. Wedbush boosted their price target on Pyxis Oncology from $6.00 to $8.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pyxis Oncology in a research report on Friday, September 25th. Wells Fargo & Company lifted their price objective on Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Finally, HC Wainwright boosted their price objective on Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, September 10th.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors have recently bought and sold shares of the business. Commonwealth Equity Services LLC boosted its holdings in shares of Pyxis Oncology by 14.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock valued at $114,000 after purchasing an additional 6,295 shares in the last quarter. T3 Companies LLC acquired a new position in shares of Pyxis Oncology during the 3rd quarter worth $61,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Pyxis Oncology by 22.0% during the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after buying an additional 160,300 shares in the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.

Pyxis Oncology Stock Up 1.2%

Shares of NASDAQ:PYXS opened at $1.66 on Thursday. The stock’s 50-day moving average is $2.57 and its 200-day moving average is $2.16. Pyxis Oncology has a 52-week low of $1.03 and a 52-week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, analysts expect that Pyxis Oncology will post -1.21 earnings per share for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.